Cargando…

Novel API Coated Catheter Removes Amyloid-β from Plasma of Patients with Alzheimer’s Disease

Alzheimer’s disease (AD) is the most common cause of dementia, characterized by the deposition of Amyloid-beta (Aβ) plaques in the brain. We have previously developed Amytrap peptide (the active pharmacological ingredient, API) and linked it to a sepharose bead matrix by click chemistry to form Amyt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chhipa, Rishi Raj, Gandbhir, Omkar, Le, Hao, Sankar, Sadhana, Sundaram, Pazhani
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612462/ https://www.ncbi.nlm.nih.gov/pubmed/34825129 http://dx.doi.org/10.24966/and-9608/100055

Ejemplares similares

‘Amytrapper’, a Novel Immobilized Sepharose API Matrix, Removes Amyloid-β from Circulation in vitro
por: Gandbhir, Omkar, et al.
Publicado: (2019)

Pre-Clinical Safety and Efficacy Evaluation of Amytrap, a Novel Therapeutic to Treat Alzheimer’s Disease
por: Gandbhir, Omkar, et al.
Publicado: (2019)

Plasma β-amyloid in Alzheimer’s disease and vascular disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Associations of plasma angiostatin and amyloid-β and tau levels in Alzheimer’s disease
por: Cheng, Yuan, et al.
Publicado: (2022)

Dietary Glycemic Load and Plasma Amyloid-β Biomarkers of Alzheimer’s Disease
por: Gentreau, Mélissa, et al.
Publicado: (2022)

Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes
por: Verberk, Inge M. W., et al.
Publicado: (2018)

Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque–removing agent, in patients with Alzheimer’s disease
por: Kandadi Muralidharan, Kumar, et al.
Publicado: (2021)

The global Alzheimer's Association round robin study on plasma amyloid β methods
por: Pannee, Josef, et al.
Publicado: (2021)

Plasma amyloid-β ratios in autosomal dominant Alzheimer’s disease: the influence of genotype
por: O'Connor, Antoinette, et al.
Publicado: (2021)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

Correlations of amyloid-β concentrations between CSF and plasma in acute Alzheimer mouse model
por: Cho, Soo Min, et al.
Publicado: (2014)

Plasma amyloid β levels in Alzheimer’s disease and cognitively normal controls in Syrian population
por: Manafikhi, Rafah, et al.
Publicado: (2021)

Integration of amyloid-β oligomerization tendency as a plasma biomarker in Alzheimer's disease diagnosis
por: Pyun, Jung-Min, et al.
Publicado: (2023)

Plasma Amyloid Concentration in Alzheimer’s Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer’s Disease Cases from Controls
por: Feinkohl, Insa, et al.
Publicado: (2020)

The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review
por: Brand, Abby L., et al.
Publicado: (2022)

Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease
por: Cullen, Nicholas C, et al.
Publicado: (2023)

The Correlations Between Plasma Fibrinogen With Amyloid-Beta and Tau Levels in Patients With Alzheimer’s Disease
por: Fan, Dong-Yu, et al.
Publicado: (2021)

Patients with Alzheimer’s disease have an increased removal rate of soluble beta-amyloid-42
por: Zaretsky, Dmitry V., et al.
Publicado: (2022)

Plasma Exosomes Spread and Cluster Around β-Amyloid Plaques in an Animal Model of Alzheimer’s Disease
por: Zheng, Tingting, et al.
Publicado: (2017)

Application of Bézier Curves for Calculating Likelihood Ratios for Plasma Amyloid-β Biomarkers for Alzheimer's Disease
por: Fierz, Walter
Publicado: (2018)

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2021)

β-Amyloid Degradation and Alzheimer's Disease
por: Wang, Deng-Shun, et al.
Publicado: (2006)

Mitochondria, Amyloid β, and Alzheimer's Disease
por: Readnower, Ryan D., et al.
Publicado: (2011)

The Amyloid-β Pathway in Alzheimer’s Disease
por: Hampel, Harald, et al.
Publicado: (2021)

The Correlations of Plasma and Cerebrospinal Fluid Amyloid-Beta Levels with Platelet Count in Patients with Alzheimer's Disease
por: Sun, Hao-Lun, et al.
Publicado: (2018)

Abnormal amyloid β(42) expression and increased oxidative stress in plasma of CKD patients with cognitive dysfunction: A small scale case control study comparison with Alzheimer's disease
por: Vinothkumar, G., et al.
Publicado: (2017)

Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
por: Toledo, Jon B, et al.
Publicado: (2013)

A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease
por: Ashton, Nicholas J., et al.
Publicado: (2019)

Plasma Oligomeric Beta Amyloid in Alzheimer's Disease with History of Agent Orange Exposure
por: Yang, YoungSoon, et al.
Publicado: (2018)

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
por: Startin, Carla M., et al.
Publicado: (2019)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Comparison of Plasma Lipoprotein Composition and Function in Cerebral Amyloid Angiopathy and Alzheimer’s Disease
por: Bonaterra-Pastra, Anna, et al.
Publicado: (2021)

Synthesis, characterization, and preclinical validation of a PET radiopharmaceutical for interrogating Aβ (β-amyloid) plaques in Alzheimer’s disease
por: Sundaram, Guruswami SM, et al.
Publicado: (2015)

Facile coating of urinary catheter with bio–inspired antibacterial coating
por: Yassin, Mohamed A., et al.
Publicado: (2019)

AMPK regulated metabolic programing: oncogenic or growth suppressive? Evolving lessons from genetic and pharmacologic studies
por: Liu, Xiaona, et al.
Publicado: (2014)

Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease
por: Wang, Min Jeong, et al.
Publicado: (2017)

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer’s disease
por: Chatterjee, Pratishtha, et al.
Publicado: (2019)

Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer’s disease
por: Meng, Xue, et al.
Publicado: (2019)

Modulation of Amyloid-β and Tau in Alzheimer’s Disease Plasma Neuronal-Derived Extracellular Vesicles by Cerebrolysin® and Donepezil
por: Alvarez, X. Anton, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h8gokkim51qeonsbgpm6t6s8g1